GlassScriptPhysician profile
Bella Fradlis
NPI 1609004209
$12,744.27
in general payments reported to CMS, 2019-2025
27 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $16.48 · 2021: $378 · 2022: $2,987 · 2023: $2,929 · 2024: $3,059 · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,190 · Education: $503 · Consulting Fee: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,190.32 |
| Education | $502.63 |
| Consulting Fee | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,090.16 | 2019-2025 | |
| Janssen Biotech, INC. | $1,875.42 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $1,338.27 | 2021-2025 | Saphnelo |
| Amgen INC. | $1,280.33 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,154.08 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $687.54 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $658.78 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $651.63 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $633.78 | 2019-2025 | |
| Pfizer INC. | $502.91 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $345.67 | 2023-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $287.77 | 2022-2025 | Orencia |
| Sandoz INC. | $209.39 | 2023-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.62 | 2023-2025 | Cyltezo, Ofev |
| Actelion Pharmaceuticals US, INC. | $136.08 | 2023-2025 | Opsumit, Opsynvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $134.25 | 2024-2025 | Tymlos |
| Horizon Therapeutics Plc | $125.40 | 2020-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $102.00 | 2023 | Idacio |
| Organon LLC | $80.60 | 2023-2024 | Renflexis, Hadlima |
| Celltrion USA INC. | $72.30 | 2023-2025 | Yuflyma, Vegzelma |
| Ani Pharmaceuticals, INC. | $52.23 | 2023-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $26.48 | 2024 | |
| Antares Pharma, INC. | $25.00 | 2021 | |
| Genentech USA, INC. | $22.81 | 2024 | Actemra |
| Celgene Corporation | $21.94 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.13 | 2024 | Arcalyst |
| Sobi, INC | $14.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bella Fradlis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.